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Cardiac Function and Heart Failure
± 0.2 / -1.4 ± 0.4 SD, r = -0.24, p<0.01), Z-score (0.7 ± 0.5 / -0.2 ± 0.1 / -0.3 ± 0.2 / -0.9 ±
0.3 SD, r = -0.22, p<0.01). Osteopenia (T-score < -1.0) was found in 20% and 29% pts in
NYHA I-II and III-IV, respectively, and osteoporosis (T-score < -2.5) in 9% pts in NYHA III-
IV. There were no osteopenia or osteoporosis in controls. CHF pts with osteopenia or
osteoporosis compared to pts with normal BMC had reduced peak VO2 (13.9±0.9 vs
16.5±0.8 mL/kg/min), decreased fat and lean mass (17±1 vs 23±1 kg, 52±1 vs 57±1 kg,
respectively), increased C-reactive protein level (48±37 vs 13±5 mg/L), increased par-
athormone level (113±18 vs 73±10 pg/mL), reduced levels of dehydroepiandrosterone
sulphate, total, free and bioavailable testosterone (54±10 vs 97±15 µg/dL, 3.0±0.6 vs
4.5±0.3 ng/mL, 9±2 vs 16±2 ng/dL, 212±49 vs 367±36 ng/dL, respectively) (all p<0.05).
During the 18-month follow-up, 18 (15 %) pts died. Reduced bone mass (BMC-total < vs
> 3 kg) was related to poor survival in univariate analysis (RR=3.7, 95%CI - 1.2-11.3,
p<0.05), not when adjusted for NYHA class, peak VO2.
Conclusions. Bone loss accompanied by reduced fat and lean mass is observed in CHF
pts, in particular in advanced stages, and is related to poor outcome. Hyperparathyroid-
ism, adrenal and gonadal andropenia, inflammation may be important in the pathogene-
sis of bone loss in CHF, but further studies are needed.
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Echocardiographic, and Neurohormonal Predictors of 
Outcome in Heart Failure Patients (Val-HeFT Data)
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Roberto Latini, Aldo P. Maggioni, Jay N. Cohn, Gianni Tognoni, Istituto di Ricerche 
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CA
Introduction: Numerous variables are prognostic of HF, but not all are widely available.
Val-HeFT data which contain a full complement of bedside, laboratory, echocardio-
graphic, and neurohormonal endpoints were analyzed for comparative predictive value.
Methods: Pooled baseline data from the history (H), physical examination (PE), and labo-
ratory from Val-HeFT included age, sex, etiology, NYHA class, symptoms, signs, labora-
tory, EF and LVIDd. Except for age, continuous variables were considered above and
below the median. Adjusted RR for mortality at study endpoint and 95% CI from a multi-
variate Cox analysis with stepwise selection are presented. Results: Patients with all data
available (N=4284) were predominantly white, aged 63 y, males/ females=4/1, 98%
NYHA class II & III, 57% ischemic etiology, EF=26.8±7.2% (mean±SD),
LVIDd=6.9±0.9cm. 828 patients died over 23 months follow-up. BNP, LVIDd, NE and cre-
atinine were the strongest independent predictors of mortality. The other significant pre-
dictors were variables from the H & PE. Leg, thigh or sacral edema showed a high RR
but a low prevalence; high grade of dyspnea on effort increased the RR > 30% (table).
NYHA class and EF were not statistically significant. Conclusions: Independent markers
of mortality were findings from the H & PE, review of systems, laboratory, and M-mode
echocardiography. Therefore, conventional bedside evaluation with a limited set of labo-
ratory data can provide a powerful aggregate for predicting mortality.
1108-119 Clinical Outcome in Patients With Preoperative 
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Bypass Graft Surgery
Mohan Babapulle, Kristian B. Filion, Seema Haider, Louise Pilote, Mark J. Eisenberg, 
Jewish General Hospital, Montreal, PQ, Canada
Background: Coronary artery bypass graft surgery (CABG) is frequently performed in
patients with chronic congestive heart failure (CHF). However, there have been no large-
scale studies specifically examining clinical outcome in patients with pre-operative CHF
undergoing CABG.
Methods: We extracted data from the resource and cost accounting systems of 5 U.S
and 4 Canadian hospitals on 12,017 consecutive patients undergoing CABG between
1997-2001. Of these patients 1,176 (9.8%) had pre-operative CHF, and 10,841 (90.2%)
did not. We examined the post-operative length of stay (LOS) and in-hospital mortality in
patients with and without CHF. We performed a log transformation of LOS data, and iden-
tified independent predictors of LOS using a multiple linear regression model. We
adjusted for covariates of mortality using multivariate logistic regression.
Results: Patients with pre-operative CHF were older (69.9 ± 9.8 years vs. 64.9 ± 10.2
years), and were more likely to be female (65.0% vs. 77.2%), to have diabetes (36.9% vs.
24.9%) and to have cerebrovascular disease (10.2% vs. 5.1%). The CHF group was also
more likely to undergo non-elective CABG (69.9% vs. 55.2%) and reoperation (8.9% vs.
5.6%). Compared to patients without CHF, patients with CHF had a longer unadjusted
post-operative LOS (11.0 ± 0.5 days vs. 6.8 ± 0.07 days). After adjusting for clinical differ-
ences, the LOS in CHF patients was 38% longer than those without CHF (95% Confi-
dence Interval (CI) 33-43%, P<0.0001). Patients with CHF also had a higher unadjusted
in-hospital mortality rate compared to patients without CHF (6.0% vs. 1.3%). The
adjusted odds ratio for mortality was 3.52 (95% CI 2.36-5.25, P<0.0001).
Conclusions: Compared to patients without pre-operative CHF, patients with pre-opera-
tive CHF have a longer post-operative LOS, and a more than 3-fold higher in-hospital
mortality rate following CABG.
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O'Connor, James G. Jollis, Duke Clinical Research Institute, Durham, NC
Background:Perioperative care has reduced the complications in patients with coronary
artery disease (CAD) undergoing major noncardiac surgery but outcomes of heart failure
(HF) patients are unknown.
Methods: Using the 1997-98 Standard Analytic File 5% Sample of Medicare beneficia-
ries, we identified pts with an index HF admission. From this cohort, we identified pts with
a subsequent major noncardiac surgery within one year of the index HF hospitalization.
We used a multivariable logistic regression model to provide adjusted mortality and read-
mission rates in pts after noncardiac surgery. Patients hospitalized with CAD and later
had a major noncardiac surgery as well as the remaining pts (Control) who had similar
surgery served as reference groups.
Results: There were 23,340 HF pts and 28,710 CAD pts who were hospitalized and sur-
vived to discharge. In the next year, there were 1,532 HF pts (6.56%) and 1,757 (6.12%)
CAD pts who underwent surgery. There were 44,512 pts in the Control group. After
accounting for demographics and comorbid conditions, the risk adjusted inpatient and
30-day mortality in discharged pts was HF-15.8%, CAD- 8.0% and Control-7.3%
(p<0.001). The risk-adjusted 30-day readmission rate was HF- 21.0%, CAD-14.3% and
Control-11.0% (p<0.001).
Conclusion: HF patients undergoing major noncardiac surgery suffer significant morbidity
and mortality despite advances in perioperative care while patients with CAD have simi-
lar mortality compared to a more general population.
1108-121 Survival Benefit With Spironolactone Therapy Is Not 
Related to Reduced hsCRP Levels in Severe Congestive 
Heart Failure: Results From a RALES Substudy
Michel F. Rousseau, Annie R. Robert, Ronald Van Beneden, Virginie de Coninck, Sylvie 
A. Ahn, Jean-Marie Ketelslegers, Hubert G. Pouleur, University of Louvain, Brussels, 
Belgium
In the RALES study, Spironolactone (Spiro), an aldosterone receptor antagonist,
decreased mortality and morbidity in patients with severe congestive heart failure. To
clarify the mechanism of action, particularly the role of inflammation on progression of
heart failure and cardiovascular events, the effects of Spiro (25 mg/daily) on plasma con-
centrations of high sensitivity C-reactive protein (hsCRP) were assessed in a subset of
113 patients (NYHA III-IV, mean EF : 25%) at entry (T0) into study, at 3 months (T3) and
at 6 months (T6) and compared the changes to the Placebo group. 54 patients were
included in the Spiro group and 59 in the Placebo group. Results were expressed in mg/
dL, geometric mean [95% CI] and data were compared using a Student t-test on a
logtransformed scale. The hsCRP changes from baseline are expressed by the ratios T3/
T0 and T6/T0 (see table).
At baseline, hsCRP levels were elevated with no significant differences between groups.
During follow-up, similar hsCRP reductions from baseline were observed in Placebo and
Spiro groups reaching statistical significance at T6 (-40%, p=0.02 and -41%, p=0.02,
respectively), with values close to normal. None of the between groups comparisons
reached statistical significance.
Thus, in this small cohort of patients with severe congestive heart failure, there was no
Covariate Frequency(%) RR [95%CI] Chi-
Square 
p_value
BNP>97 pg/mL 50 1.85 [ 1.56 - 2.15] 61 <.0001
LVIDd>6.8 cm 54 1.49 [1.23 - 1.72] 28 <.0001
Norepinephrine>394 pg/
mL
50 1.39 [1.21 - 1.61] 20 <.0001
Creatinine>107 µmol/L 51 1.40 [1.21 - 1.61] 20 <.0001
Edema leg/thigh/sacrum 2 2.01 [1.45 - 2.77] 18 <.0001
Digoxin prescribed 67 1.40 [1.19 - 1.65] 16 <.0001
Age>70y 29 1.33 [1.14 - 1.54] 14 0.0002
Ischemic Etiology 57 1.32 [1.14 - 1.54] 14 0.0002
Dyspnea on effort 3+/4+ 33 1.30 [1.12 - 1.50] 12 0.0004
BB not prescribed 65 1.31 [1.12 - 1.54] 12 0.0006
Paroxysmal nocturnal 
dyspnea
9 1.40 [1.14 - 1.72] 10 0.0014
Systolic BP<121 mmHg 49 1.23 [1.07 - 1.42] 9 0.0032
BMI >22 kg/m2 10 1.32 [1.08 - 1.60] 8 0.0055
